Oruka Therapeutics priced an upsized $700 million public offering, raising cash and marketable securities to $1.1 billion, enough to fund operations through a Biologics License Application filing for its lead candidate. The Capital infusion eases financing pressure and positions the company to Capitalize on forthcoming Phase‑3 data, supporting a clearer valuation trajectory.

Key Highlights

  • Upsized $700 million Equity offering represents roughly 12 % of Oruka’s $6.0 billion Market Capitalisation .
  • Post‑offering cash, cash equivalents and marketable securities total $1.1 billion.
  • Phase 2a EVERLAST‑A results showed 63.5 % of participants achieving PASI 100 at Week 16.

Upsized $700M Offering

The upsized equity raise represents about 12 % of Oruka’s $6.0 billion market capitalisation, underscoring the material scale of the transaction. By expanding its Balance Sheet , the company reduces immediate financing risk and secures resources for its pipeline, notably the planned Phase‑3 program for ORKA‑001. The offering’s size also signals confidence from investors despite a modest Earnings miss, and it dampens pressure to seek higher‑cost Debt amid a market that currently reflects an 18 % short interest and 6.2 days to cover.

The additional capital therefore cushions the company against market Volatility while it pursues key clinical milestones.

Cash Position and Expense Surge

Following the offering, cash, cash equivalents and marketable securities sit at $1.1 billion, a level that comfortably exceeds the runway needed for the upcoming BLA submission. Research and Development expenses climbed to $43.3 million, driven by expanded trial activity and a non‑refundable upfront payment to Halozyme. General and administrative costs rose to $6.9 million, reflecting higher compensation as the firm scales its public‑company functions.

Other income increased to $8.9 million, mainly from interest on the larger cash balance, offsetting part of the net loss. Together, these figures illustrate a higher Burn Rate that the fresh capital is explicitly designed to sustain.

Clinical Progress Fuels Future Value

The company reported strong Phase 2a data from its EVERLAST‑A study, where 63.5 % of participants achieved complete skin clearance (PASI 100) at Week 16, alongside 83 % reaching PASI 90 and 84 % attaining IGA 0/1. Enrollment for the Phase 2b EVERLAST‑B trial finished at 187 subjects, with Week 16 readouts slated for the fourth quarter of 2026. Parallel programs include ORCA‑SURGE, expecting Q1 2027 data, and the initiation of ORCA‑SPLASH in hidradenitis suppurativa.

Sector peers displayed mixed movement on the same day, with SRRK up 1.4 % while CAI and ERAS fell, highlighting the relative resilience of Oruka’s stock. The upcoming data sets are likely to shape investor sentiment and price momentum.

Next Catalyst: Q4 2026 EVERLAST‑B Data

Oruka’s near‑term focus centers on the Week 16 results from the EVERLAST‑B trial, scheduled for release in the fourth quarter of 2026. In addition, longer‑term readouts from EVERLAST‑A at the end of 2026 will further clarify durability of response. Investors will watch these milestones closely, as they will either validate the current cash runway or prompt a reassessment of financing needs ahead of the BLA filing.

The timeline frames the next critical window for value creation.

Peers Moving on This News

  • Scholar Rock Holding Corp (SRRK) up 1.4%
  • Caris Life Sciences Inc (CAI) down 0.3%
  • Erasca Inc (ERAS) down 0.9%

Analysis based on the Form 8-K filed 10 August 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making Investment decisions.